Isoform Oncology is pioneering the development of novel cancer biotherapeutics by exploiting isoform switching and alternative splicing.
We address a critical care gap for refractory patients - those who lack key targets or have developed resistance to blockbuster treatments.
Alternative splicing generates disease-specific protein variations and is often hijacked in cancer, creating unique, actionable targets that remain untapped by conventional therapies.
By identifying and drugging these cancer-specific isoforms, we aim to selectively attack and kill tumor cells, offering new hope for patients who currently have no effective options.
Larcombe
CEO co-founder
Experienced founder. Computational biologist, BSc in genetics, PhD in synthetic antigen design for antibody development.
Morgan
CSO co-founder
Translational biologist, BSc and MSc in biomedical science, MA in healthcare law & ethics, PhD in variant splice targets in cancer.
Moll
Scientific Advisor
Industry leader in oncology drug discovery. Boehringer-Ingelheim, Sanofi, Pfizer.
Patients deserve precise and effective medicines that work:
On target. On time. Every time.